Company Overview
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company focused on developing advanced therapies for acute myeloid leukemia and other blood cancers. The company functions within the Healthcare sector, specifically the Biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory hurdles before products reach commercialization. This biotechnology entity maintains a market capitalization of $525.23M and employs 154 individuals to advance its clinical pipeline. The valuation metrics indicate that the company is priced at a significant premium relative to its reported revenue, which is consistent with clinical-stage biotechs that prioritize asset development and future potential over current profitability, as evidenced by the absence of trailing or price-to-sales revenue figures in the financial data.
Financial Health
The company reported a net income of $-2,449,551,104 for the trailing twelve months, while revenue and EBITDA figures are not available for standard reporting periods, a common characteristic for pre-commercial biotechnology firms where costs vastly outpace current sales. The substantial gap between reported revenue and net income reveals a cost structure dominated by research, development, and operational expenses typical of clinical-stage operations where product sales have not yet offset the heavy investment in genome-editing technologies. Free cash flow stands at $-183,391,376, indicating that the company is burning through its financial reserves to fund its clinical trials and platform development rather than generating surplus cash for immediate distribution. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the lack of commercial revenue to generate profit on sales and the heavy weighting of fixed costs in the current business model. Despite the negative income, the balance sheet shows a cash position of $170.46M against total debt of $3.06M, suggesting a highly conservative leverage profile given the minimal debt burden relative to liquid assets. The current ratio is reported at 9.16, a figure that indicates strong short-term liquidity and the ability to cover current obligations many times over with existing assets. Return on Equity is not available for calculation due to the financial structure, while Return on Assets is recorded at -144.3%, a metric that reveals management is currently utilizing the asset base to generate significant losses rather than positive returns on invested capital.
Valuation Assessment
Valuation multiples for the company present a complex picture, with a trailing P/E ratio listed as N/A and a forward P/E of -2.53, which implies that expected earnings are anticipated to remain negative or that the market is pricing the stock based on non-earnings fundamentals common in clinical-stage development. The price-to-book ratio is recorded at -0.05, a negative figure that indicates the market capitalization is effectively below the book value of shareholders' equity, a scenario often seen in distressed or high-risk biotechnology assets where market sentiment discounts the underlying assets significantly. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A, while the EV/EBITDA stands at 0.13, suggesting the enterprise value is extremely low relative to earnings before interest, taxes, depreciation, and amortization, though the negative earnings render traditional multiples less meaningful for comparison. The stock has experienced extreme volatility, trading between a 52-week low of $2.62 and a 52-week high of $65.80, placing the current price trajectory within a range that reflects the high-risk nature of clinical-stage biotechnology investments. The beta value is 2.04, indicating that the stock price is expected to be twice as volatile as the broader market, a characteristic typical of small-cap biotechnology companies that experience sharp price swings based on clinical trial results or regulatory news.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, which is standard for companies in the clinical stage that have not yet achieved commercial revenue or consistent profitability. Since the company is not a dividend payer, there is no dividend yield or payout ratio to evaluate, meaning the company retains all earnings to reinvest into its Vor Bio platform and the development of tremtelectogene empogeditemcel rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology firms that must allocate capital toward expanding their pipeline and conducting further clinical trials to achieve market entry. The overall growth and income profile is defined by a complete reliance on future commercial success rather than current cash generation or dividend distributions, creating a high-risk, high-potential scenario dependent on the successful clinical development of its genome-edited hemato therapies.